ViCToRy: Vorasidenib in Combination With Tumor Specific Peptide Vaccine for Recurrent IDH1 Mutant Lower Grade Gliomas

Abroad (travel likely)RecruitingPHASE1

Conditions

Low Grade Glioma of Brain

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Duke University Medical Center, Durham, North Carolina, United States
Contact: Study coordinator (Katherine Peters, MD, PhD) · dukebrain1@duke.edu · 919-684-5301
Contact: Study coordinator (Stevie Threatt) · dukebrain1@duke.edu · 919-684-5301

Study leads

Katherine Peters, MD, PhD
Principal Investigator
Duke University

View source on ClinicalTrials.gov Contact study team (email)